Technical Analysis for FOLD - Amicus Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 12.31 0.08% 0.01
FOLD closed up 0.08 percent on Friday, January 18, 2019, on 77 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical FOLD trend table...

Date Alert Name Type % Chg
Jan 18 Slingshot Bullish Bullish Swing Setup 0.00%
Jan 18 Doji - Bearish? Reversal 0.00%
Jan 18 Outside Day Range Expansion 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 18 Up 3 Days in a Row Strength 0.00%
Jan 18 Up 4 Days in a Row Strength 0.00%
Jan 17 Narrow Range Bar Range Contraction 0.08%
Jan 17 NR7 Range Contraction 0.08%
Jan 17 Wide Bands Range Expansion 0.08%

Older signals for FOLD ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs known as pharmacological chaperones. It develops pharmacological chaperones as next-generation medicines for a range of rare and orphan diseases with a focus on improved therapies for lysosomal storage disorders. The company's development programs include small molecules as monotherapy treatments for Fabry and other lysosomal storage diseases, and enzyme replacement therapy (ERT). Its chaperone-advanced replacement therapy programs comprise chaperones co-administered with currently marketed ERTs, as well as proprietary therapeutic enzymes co-formulated with pharmacological chaperones as next-generation ERTs. The company's primary product includes migalastat HCl, a product candidate for Fabry disease that is in Phase III global registration studies for patients with genetic mutations. Its products also comprise AT2220, which has completed Phase II safety used for the treatment of Pompe disease; and AT3375 and afegostat tartrate that are in preclinical studies used for treating Gaucher disease. The company has strategic collaboration with GlaxoSmithKline PLC to develop and commercialize migalastat HCl. Amicus Therapeutics, Inc. was founded in 2002 and is based in Cranbury, New Jersey.
Is FOLD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 1 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 17.62
52 Week Low 8.27
Average Volume 2,652,731
200-Day Moving Average 13.2447
50-Day Moving Average 10.5488
20-Day Moving Average 10.6035
10-Day Moving Average 11.761
Average True Range 0.6028
ADX 27.1
+DI 28.3288
-DI 13.5357
Chandelier Exit (Long, 3 ATRs ) 10.6816
Chandelier Exit (Short, 3 ATRs ) 10.0784
Upper Bollinger Band 13.2132
Lower Bollinger Band 7.9938
Percent B (%b) 0.83
BandWidth 49.22337
MACD Line 0.5371
MACD Signal Line 0.3164
MACD Histogram 0.2207
Fundamentals Value
Market Cap 2.03 Billion
Num Shares 165 Million
EPS -1.47
Price-to-Earnings (P/E) Ratio -8.37
Price-to-Sales 135.92
Price-to-Book 7.22
PEG Ratio -0.17
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.99
Resistance 3 (R3) 12.97 12.73 12.87
Resistance 2 (R2) 12.73 12.56 12.74 12.83
Resistance 1 (R1) 12.52 12.45 12.40 12.54 12.80
Pivot Point 12.28 12.28 12.22 12.29 12.28
Support 1 (S1) 12.07 12.11 11.95 12.09 11.82
Support 2 (S2) 11.83 12.00 11.84 11.79
Support 3 (S3) 11.62 11.83 11.75
Support 4 (S4) 11.64